WO1989005155A1 - Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales - Google Patents

Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales Download PDF

Info

Publication number
WO1989005155A1
WO1989005155A1 PCT/US1988/004118 US8804118W WO8905155A1 WO 1989005155 A1 WO1989005155 A1 WO 1989005155A1 US 8804118 W US8804118 W US 8804118W WO 8905155 A1 WO8905155 A1 WO 8905155A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
ecr
cells
molecules
monoclonal antibody
Prior art date
Application number
PCT/US1988/004118
Other languages
English (en)
Inventor
David A. Cheresh
Original Assignee
Scripps Clinic And Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic And Research Foundation filed Critical Scripps Clinic And Research Foundation
Publication of WO1989005155A1 publication Critical patent/WO1989005155A1/fr
Priority to FI893475A priority Critical patent/FI893475A/fi
Priority to NO89892941A priority patent/NO892941L/no
Priority to DK355589A priority patent/DK355589A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a monoclonal antibody that immunoreacts with the RGD- directed adhesion receptor of endothelial cells (ECr) , and thereby inhibits the binding of endothelial cells to the RGD-containing matrix proteins vitronectin, fibrinogen and von Willebrand factor. Also contemplated are therapeutic methods wherein a monoclonal antibody of the present invention is used to inhibit the adhesion of endothelial cells to the subendothelial matrix and thereby modulate tumor growth.
  • ECr endothelial cells
  • Cell adhesion is a critical process in tumor growth because it plays a role in the formation and vascularization of new tumor tissue. Therefore, agents that inhibit cell adhesion can be used therapeutically to inhibit tumor growth.
  • Cell adhesion generally involves recognition of specific adhesive proteins by cell surface. receptors.
  • the cell surface receptors of present interest specifically bind to matrix proteins at sites that have as a part of their structure the tripeptide amino acid residue sequence Arg-Gly-Asp (RGD) .
  • RGD tripeptide amino acid residue sequence Arg-Gly-Asp
  • Such receptors are known in the art as RGD-directed adhesion receptors.
  • the binding specificity of individual RGD-directed adhesion receptors appears to depend on the structural milieu within which the RGD tripeptide is found.
  • RGD-directed adhesion receptors are further characterized as consisting of non- covalently associated alpha and beta subunits, i.e., they are heterodimeric protein complexes.
  • Exemplary RGD-directed adhesion receptors are vitronectin receptor, fibronectin receptor and GpIIb-IIIa, all of which are distinguishable on the basis of their subunit composition and the proteins which they specifically bind.
  • ECr RGD-directed adhesion receptor
  • ECr isolated from M21 cells is a heterodimer consisting of alpha and beta subunits which under reducing conditions display molecular weights of about 130 kilodaltons (kDa) and 105 kDa, respectively, when analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) .
  • ECr is also found on the surface of human umbilical vein endothelial (HTJVE) cells.
  • HTJVE human umbilical vein endothelial
  • monoclonal antibody LM609 immunoreacts with HUVE cells and thereby inhibits their binding to fibrinogen, vitronectin and von Willebrand factor, indicating that the RGD-directed receptor recognized by LM609 on HUVE cells has the same ligand specificity (matrix protein binding profile) as ECr.
  • a monoclonal antibody designated 7E3, raised against GpIIb-IIIa, an RGD- directed adhesion receptor found on human platelets, could immunoreact not only with GpIIb-IIIa, but also with a heterodimeric RGD-directed adhesion receptor on HUVE cells having alpha and beta subunits displaying molecular weights of about 130 kDa and 105 kDa, respectively, i.e., molecular weights similar to those of ECr but distinguishably different from GpIIb-IIIa.
  • ECr and GpIIb-IIIa appear to share at least one immunologically cross-reactive epitope.
  • Monoclonal antibody 7E3 was also shown by Charo et al. to be capable of immunoreacting with HUVE cells and blocking their attachment to substrates containing fibrinogen and von Willebrand factor, and partially blocking their attachment and spreading on vitronectin, thus indicating that the receptor recognized by 7E3 on HUVE cells has a similar matrix protein binding profile as ECr.
  • the present invention provides a monoclonal antibody comprising antibody molecules that immunoreact with ECr present on HUVE cells and thereby inhibits the adhesion of those cells to vitronectin, fibrinogen or von Willebrand factor.
  • the anti-ECr antibody present in the monoclonal antibody are those produced by the hybrido a having ATCC designation HB9537.
  • the present invention contemplates a hybridoma that produces antibody molecules that immunoreact with ECr present on HUVE cells and thereby inhibits the adhesion of those cells to vitronectin, fibrinogen or von Willebrand factor. Also contemplated is a method of inhibiting tumor growth in a subject.
  • the method comprises administering, in a pharmaceutically acceptable excipient a therapeutically effective amount of a monoclonal antibody comprising antibody molecules that immunoreact with ECr present on HUVE cells and thereby inhibits the binding of those cells to vitronectin, fibrinogen, and von Willebrand factor.
  • invention is a method of assaying for the presence of ECr in a body sample.
  • the method comprises forming an immunoreaction admixture by admixing a body sample to be assayed with a monoclonal antibody of the present invention.
  • the admixture is maintained for a time period sufficient for any ECr present in the sample to immunoreact with the monoclonal antibody to form a
  • ECr-antibody immunoreaction product Assaying for the presence of any ECr-antibody immunoreaction product formed thereby provides a means for detecting the presence ECr in the sample. Still further contemplated is a method of assaying in vivo for the presence of ECr in a subject.
  • the method comprises intravenously administering to a subject a diagnostically effective amount of a monoclonal antibody of the present invention that is linked to an in vivo indicating means and dispersed in a physiologically tolerable excipient.
  • the subject is then maintained for a predetermined time period sufficient for the administered monoclonal antibody to immunoreact in vivo with any ECr present in the subject to form an immunoreaction product.
  • Assaying for the presence and preferably the location of any immunoreaction product formed within the subject thereby provides a means for detecting the presence of ECr in vivo.
  • the present invention also contemplates a diagnostic system in kit form useful for performing the contemplated assay methods.
  • the system comprises a container that includes a monoclonal antibody of the present invention present in an amount sufficient to carry out at least one assay.
  • the present invention provides several benefits and advantages.
  • One benefit provided by the present invention is that the contemplated monoclonal antibody provides a means for detecting the presence of ECr protein in a body sample and in a subject in vivo.
  • the monoclonal antibody of the present invention inhibits adhesion of ECr- containing cells to vitronectin, fibrinogen and von Willebrand factor, the present invention provides a therapeutic composition for inhibiting tumor cell growth.
  • An advantage provided by the present invention derives from the specificity that the contemplated monoclonal antibody has for ECr and not -6-
  • contemplated methods for detecting the presence of ECr in body samples and in vivo can advantageously distinguish ECr from other RGD-directed adhesion receptors such as VNr or FNr.
  • the immunoreaction specificity of the contemplated monoclonal antibody limits the effects of inhibition of cell adhesion to only those cells bearing ECr.
  • Figure 1 illustrates an autofluorogram of the immunoreaction product that forms with ECr present in M21 cell lysates using the ECr-specific monoclonal antibody that contains antibody molecules produced by hybridomas LM142 or LM609.
  • the M21 cell proteins, including ECr had 35 S-methionine labeled by pulsing a M21 cell culture with 35 S-methionine for 10 min and then chasing with unlabeled L-methionine for either 0 hours, i.e., zero time cells (lanes A and C) , or for 8 hours (lanes B and D) .
  • the resulting immunoreaction products were electrophoresed under reducing conditions in a 7.5% polyacrylamide gel as described in Example 4.
  • Mab LM142 immunoreacts with a protein of about 160 kDa in molecular weight previously shown to be a biosynthetic precursor to the M21 cell ECr alpha subunit. Cheresh et al., J. Biol. Chem.. 262:1434-37 (1987). After 8 hours of chase. Lane B illustrates that ECr immunoreacts with Mab LM142 and is comprised of alpha and beta subunits of 130 kDa and 105 kDa, respectively. Similar results, shown in lanes C and D, were obtained using Mab LM609.
  • Figure 2 contains six panels that graphically illustrate the effects of Mab LM609 on the kinetics of M21 cell attachment to microtiter wells each coated with one of five different matrix proteins or the peptide GRGPSPC (adhesion substrates) .
  • 3H-leucine labeled M21 cells were first immunoreacted with 0.05 mg/ml of either Mab LM609 (0) or heterologous Mab W6/32 (0) .
  • the antibody treated cells (Mab-cell immunoreaction products) were then plated into the coated microtiter wells and maintained for the indicated times to allow the cells to adhere to the wells as described in Example 5.
  • results are expressed as the total number of cells bound, that number being a function of the cell associated label, expressed in counts per minute (cpm X 10 ⁇ 3 ) bound to the various matrix proteins after the indicated times. Each point represents the mean + one standard deviation of five replicate measurements.
  • the three lower panels demonstrate that Mab LM609 immunoreacts with and significantly inhibits the adhesion of M21 cells to, from left to right, von Willebrand factor, fibrinogen and the peptide GRGDSPC, as evidenced by the lower number of cpm detected for Mab LM609 as opposed to heterologous Mab W6/32.
  • Figure 3 is a composite figure comprising a graph in the lower portion and an autofluorogram in the upper portion that together illustrate the elution profile of HUVE cell ECr isolated on a GRGDSP - Sepharose affinity column (purified ECr) as described in Example 6.
  • An octylglucoside extract of HUVE cells whose proteins had been metabolically labeled with 35 S-methionine was passed over a GRGDSPK-Sepharose affinity matrix so as to allow any RGD-directed adhesion receptors present to bind to the matrix.
  • the matrix was then washed first with elution buffer containing 1 mg/ml of the peptide GRGESP to yield eluted fractions 1 through 10, and then with elution buffer containing the peptide GRGDSP to yield fractions 11-20.
  • the graph illustrates the elution profile of 35 S-methionine labeled proteins determined by measuring the counts per minute (cpm) of radioactivity present in a 50 ul aliquot of each fraction using a liquid scintillation counter.
  • the arrows mark the fraction in which the addition of elution buffer containing the indicated peptide to the affinity column was made.
  • the autofluorogram illustrates the elution " profile of labeled extracts when analyzed by electrophoresis on 7.5% polyacrylamide gels under reducing conditions.
  • the autofluorogram is aligned in the figure such that the lane of the gel is directly above the eluted fraction from which a 50 ul aliquot was taken for electrophoresis.
  • the apparent molecular weights (Mr) of the two protein bands found in fractions 14-18, which represent the alpha (upper) and beta (lower) subunits, respectively, are indicated in kilodaltons.
  • Figure 4 illustrates an autofluorogram of a
  • Mab LM609 and Mab LM142 each immunoreact with the endothelial ECr heterodimer complex comprised of alpha and beta subunits of about 135 kDa and 115 kDa in molecular weight, respectively.
  • the heterologous antibody 9.2.27 does not immunoreact with purified ECr.
  • Figure 5 is a series of eight panels (A-H) that contain graphs illustrating the effects of Mab LM609 on the kinetics of HUVE cell attachment to various matrix proteins (adhesion substrates) .
  • H- leucine labeled endothelial cells were first allowed to immunoreact with 0.05 mg/ml of Mab LM609 (0), heterologous Mab W6/32 (0) or growth medium alone ( ) , washed free of excess antibody, and were then plated onto microtiter wells and maintained for the indicated times to permit adhesion to the matrix proteins that had been coated onto the microtiter wells as described in Example 8.
  • the matrix proteins used were fibronectin (A) , collagen IV (B) , laminin (C) , vitronectin (D) , GRGDSPC (E) , von Willebrand factor (vWF) , pool I (F) , vWF, pool III (G) , and fibrinogen (H) .
  • the results are expressed in the same manner as described for Figure 2.
  • Panels D-H demonstrate that Mab LM609 immunoreacts with and significantly inhibits the adhesion of HUVE cells to the adhesion substrates vitronectin, von Willebrand factor, fibrinogen and the peptide GRGDSPC as evidenced by a reduction in the number of cells bound after treatment with Mab LM609 as opposed to Mab LM142 or heterologous Mab W6/32 (negative control) .
  • Figure 6 illustrates the partial amino acid residue sequence of the amino terminal portion of M21 cell ECr protein, shown from left to right and in the direction from amino-terminus to carboxy-terminus using the single letter code beginning with residue 1 as the first residue on the amino terminus.
  • the amino acid residue sequence of both the alpha and beta subunit of ECr was determined as described in Example 9. Also shown are sequences of homologous regions of the vitronectin receptor alpha subunit [Ginsberg et al., J. Biol. Chem.. 262:5437-40 (1987)], vitronectin receptor beta subunit [Takada et al., Proc. Natl. Acad. Sci. USA.
  • FIG. 7 is a bar graph illustrating the immunoreactivity of each of 5 Mabs with various tumor cell types as determined using the ELISA assay described in Example 10.
  • the Mabs used include: LM142 and LM609, directed to ECr; AP3, directed to platelet GpIIIa beta subunit; LM543, directed to fibronectin receptor beta subunit; and, W6/32, directed to a human histocompatibility antigen.
  • LM609 Mab LM609 immunoreacts significantly (>0.1 O.D.492) with the following cell lines: M21, M16A, M18, M14, A375MM, Melur and WM266.
  • Mab LM142 immunoreacts significantly with the following cell lines: M21, M16A, M18, M14, A375P, A375MM, Melur, WM266, WM239a, S -N-AS, UCLA P3, T291, Bachle, SCL-I185, Colo 357 FG and U87 MG.
  • Figure 8 illustrates an autofluorogram of a 7.5% polyacrylamide gel that was used to analyze immunoreaction products produced in a study to determine whether or not the determinants recognized by Mab LM142 (panel A) , Mab LM609 (panel B) and Mab AP3 (panel C) were complex-dependent.
  • the pulse-chase sample times are indicated in minutes (') above panels B and C. The sample times are the same for panel A as is indicated in the corresponding panel directly below in Panel B.
  • Mab LM142 is shown to have formed an immunoreaction product that contains ECr alpha subunit precursor of about 160 kDa when immunoreacted with M21 cell pulse-chase lysates prepared at time intervals ranging from zero time point (0) to 240 minutes (240'). After a chase of approximately 120 minutes (120'), Mab LM142 produced immunoreaction products that contain 130 kDa and 105 kDa proteins corresponding to the alpha and beta subunits, respectively. Mab LM142 is directed to the alpha subunit of ECr and is characterized herein as having the ability to immunoreact with a complex- independent determinant.
  • Mab LM609 is shown to have formed an immunoreaction product that contains the alpha subunit precursor when immunoreacted with the same M21 cell pulse-chase lysates as is shown in Panel A.
  • the precursor first appears after a chase of about 5 minutes (5') beyond the zero time point and continues to be detected throughout the remaining chase period to 240 minutes.
  • Mab LM609 also produced immunoreaction products after a 120 minute chase that contain the same 130 kDa and 105 kDa proteins detected when using Mab LM142 shown in panel A.
  • Mab LM609 is directed to the heterodimer complex ECr and is characterized herein as having the ability to immunoreact with a complex-dependent determinant.
  • Mab AP3 is shown in panel C to have formed an immunoreaction product containing both the alpha subunit precursor and the 105 kDa beta subunit protein when immunoreacted with the same M21 cell pulse-chase lysates as shown in Panel A.
  • the precursor and the 105 kDa proteins each appear after a chase of about 10 minutes (10') and persist throughout the chase period to 120 minutes (120').
  • Mab AP3 is directed to the platelet glycoprotein Ilia but is also shown here to immunoreact with a determinant present on the beta subunit of ECr. Detailed Description of the Invention A. Definitions
  • amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a further sequence of one or more amino acid residues up to a total of about fifty residues in the polypeptide chain.
  • Polypeptide and Peptide are terms used interchangeably herein to designate a linear series of no more than about 50 amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues *
  • Protein is a term used herein to designate a linear series of greater than 50 amino acid residues connected one to the other as in a polypeptide.
  • antibody in its various grammatical forms is used herein as a collective noun that refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope.
  • An "antibody combining site” is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.
  • antibody molecule in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.
  • Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab') 2 and F(v) .
  • Fab and F(ab')2 portions of antibodies are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods that are well known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous and Dixon.
  • Fab' antibody portions are also well known and are produced from F(ab') portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide.
  • An antibody containing intact antibody molecules are preferred, and are utilized as illustrative herein.
  • a monoclonal antibody in its various grammatical forms refers to a population of one species of antibody molecule of determined (known) antigen-specificity.
  • a monoclonal antibody contains only one species of antibody combining site capable of immunoreacting with a particular antigen and thus typically displays a single binding affinity for that antigen.
  • a monoclonal antibody may therefore contain a bispecific antibody molecule having two antibody combining sites, each immunospecific for a different antigen.
  • a monoclonal antibody (Mab) of the present invention is characterized as containing, within detectable limits, only one species of antibody combining site capable of immunologically binding (immunoreacting with) the RGD-directed adhesion receptor referred to herein as ECr.
  • the antibody molecules present in a monoclonal antibody of this invention typically display a single binding affinity for ECr even though it may contain antibody combining sites capable of binding proteins other than ECr.
  • a monoclonal antibody of the present invention is further characterized as being substantially free of antibody molecules that immunoreact with vitronectin receptor (VNr) or fibronectin receptor (FNr) described below. That is, a monoclonal antibody of this invention does not, within the limits of immunological assay procedures, immunoreact with VNr or FNr, either in isolated form or present in the lysate of a cell that expresses either or both of those receptors.
  • VNr vitronectin receptor
  • FNr fibronectin receptor
  • VNr and FNr are well known in the art and can be isolated by known methods from the human osteosarcoma cell line MG-63, available from The American Type Culture Collection, Rockville, MD under the designation ATCC CRL 1427. See for example Pytela et al., Cell, 40:191-8 (1985) and Pytela et al., Proc. Natl. Acad. Sci. USA, 82:5766-70 (1985).
  • the anti-ECr antibody molecules present in a monoclonal antibody of the present invention are further characterized as having the ability to immunoreact with endothelial cells such as HUVE cells, bovine aortic endothelial (BAE) cells, chick, embryo endothelial (CEE) cells and the like and thereby inhibit their adhesion (attachment) to vitronectin, fibrinogen, von Willebrand factor or a hexapeptide having the amino acid residue sequence GRGDSP.
  • endothelial cells such as HUVE cells, bovine aortic endothelial (BAE) cells, chick, embryo endothelial (CEE) cells and the like and thereby inhibit their adhesion (attachment) to vitronectin, fibrinogen, von Willebrand factor or a hexapeptide having the amino acid residue sequence GRGDSP.
  • a monoclonal antibody of this invention immunoreacts with ECr when it is present on the endothelial cell surface to form a cell-antibody complex that does not bind to vitronectin, fibrinogen, von Willebrand factor or the hexapeptide GRGDSP.
  • the anti-ECr antibody molecules present in a monoclonal antibody of the present invention are still further characterized as having the ability to immunoreact with a complex-dependent determinant present on ECr but incapable of immunoreaction with either the alpha or beta subunits when those subunits are not associated together in a ECr heterodimer complex.
  • An "antigenic determinant” or “determinant” is that structural portion of an antigen to which an antibody combining site immunologically binds.
  • a determinant is "complex-dependent" when it is present on the ECr heterodimer complex comprised of non- covalently associated alpha and beta subunits but not present on either the alpha or beta subunits when the subunits have not associated into a heterodimer complex.
  • a preferred monoclonal antibody of this invention contains antibody molecules capable of being produced by the hybridoma LM609 (ATCC HB 9537), i.e., monoclonal antibody LM609 (Mab LM609) .
  • LM609 ATCC HB 9537
  • monoclonal antibody LM609 Mob LM609
  • a preferred method for producing a monoclonal antibody of the present invention involves the use of hybridoma LM609, it is to be understood that a monoclonal antibody of the present invention can be produced by other well known methods.
  • Those methods include the use of a hybridoma or other cell formed by cell-fusion that produces anti-ECr antibody molecules functionally equivalent to those produced by hybridoma LM609, preferably a hybridoma that produces an anti-ECr antibody that has a paratope that is immunologically cross-reactive with the anti- ECr paratope produced by hybridoma LM609.
  • Those methods also include the use of any cell that contains an immunoglobulin heavy- or light-chain variable region-encoding DNA sequence that is homologous to the anti-ECr antibody heavy- or light-chain variable region-encoding DNA sequence present in hybridoma LM609.
  • the present invention contemplates any monoclonal antibody that is functionally the same as a monoclonal antibody of this invention produced through the use of hybridoma LM609.
  • a monoclonal antibody of the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma of the present invention, such as hybridoma LM609, that secretes antibody molecules having the immunospecificity(s) described hereinabove.
  • the culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium.
  • the antibody molecule-containing medium is then collected.
  • the antibody molecules can then be further isolated by well known techniques.
  • DMEM Dulbecco's minimal essential medium
  • DMEM Dulbecco et al., Virol. 8:396 (1959)
  • DMEM Dulbecco's minimal essential medium
  • An exemplary inbred mouse strain is the Balb/c.
  • the monoclonal antibodies produced by the above method can be used, for example, in diagnostic and therapeutic modalities wherein formation of an ECr-containing immunoreaction product is desired.
  • a hybridoma of the present invention is characterized as producing a monoclonal antibody (Mab) capable of immunoreacting with ECr.
  • a preferred hybridoma produces a Mab that is substantially free of antibody molecules that immunoreact with VNr or FNr.
  • More preferably a hybridoma of the present invention is characterized as producing a Mab capable of immunoreacting with HUVE cells, BAE cells, CEE cells and the like and thereby inhibiting their adhesion to vitronectin, fibrinogen, von Willebrand factor or a hexapeptide having the amino acid residue sequence GRGDSP.
  • hybridoma is characterized herein as being capable of immunoreaction with a complex-dependent determinant present on ECr.
  • Methods for producing hybridomas that secrete antibody molecules having a desired immunospecificity, i.e., having the ability to immunoreact with an identifiable epitope on a particular protein, are well known in the art. Particularly applicable is the hybridoma technology described by Galfre et al., Meth. Enzvmol.. 73:3-46 (1981) , which description is incorporated herein by reference.
  • a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with an immunologically effective amount of ECr.
  • the myeloma cell line be from the same species as the lymphocytes.
  • a mouse of the strain 129 G1X + is the preferred mammal.
  • Suitable mouse myelomas for use in the present invention include the hypoxanthine- aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/0-Agl4 that are available from the American Type Culture Collection, Rockville, MD, under the designations CRL 1580 and CRF 1581, respectively.
  • HAT hypoxanthine- aminopterin-thymidine-sensitive
  • Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 2000.
  • Fused hybrids are selected by their sensitivity to HAT.
  • Hybridomas capable of producing a monoclonal antibody of this invention are identified by the screening methods described in Example 2.
  • the culture supernatants from HAT selected hybridomas are screened in an ELISA assay for the presence of antibody molecules capable of immunoreaction with M21 cells.
  • Hybridomas that produced antibody molecules with the ability to immunologically bind M21 cells were retained and further screened for their ability to produce antibody molecules that could inhibit ECr- containing cells from adhering to vitronectin using the adhesion assay in Example 5.
  • Those hybridomas that produced adhesion inhibiting antibody molecules in that assay were retained as hybridomas of the present invention.
  • Preferred hybridomas of the present invention are further screened for the ability to immunoreact with a complex-dependent determinant present on the ECr heterodimer complex using the method described in Example 12.
  • hybridoma LM609 that has been deposited pursuant to Budapest Treaty requirements with the ATCC on September 15, 1987, and was assigned accession number HB 9537.
  • a monoclonal antibody of the present invention can be used to inhibit the binding interaction of ECr with vitronectin, fibrinogen and von Willebrand factor in vivo.
  • a monoclonal antibody of the present invention contains antibody molecules that immunoreact with ECr to form an antibody molecule-ECr complex, present on the endothelial cell-surface, so that the cell does not bind vitronectin, fibrinogen or von Willebrand factor.
  • a monoclonal antibody of the present invention can be used in a pharmaceutically acceptable composition that, when administered intravenously in an effective amount, is capable of inhibiting the ability of ECr molecules present on the surface of tumor cells and blood vessel-forming endothelial cells to bind vitronectin, fibrinogen and von Willebrand factor present as part of the subendothelial matrix.
  • a monoclonal antibody composition of the present invention can be used to inhibit tumor growth because such growth depends on cell attachment.
  • the monoclonal antibody compositions administered take the form of solutions or suspensions and contain 0.1-95% of active ingredient, preferably 25-70%.
  • compositions which contain antibody molecules as active ingredients are well understood in the art.
  • such compositions are prepared as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
  • the preparation can also be emulsified.
  • the active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or" the like and combinations thereof.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
  • a monoclonal antibody can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic
  • the therapeutic antibody molecule-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example.
  • unit dose when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.
  • compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount.
  • the quantity to be administered depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient without adverse side affects, and degree of inhibition of interaction desired between ECr and the appropriate matrix protein. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosage ranges are of the order of 0.1 to 10 milligrams, preferably one to several milligrams, of active ingredient per kilogram bodyweight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated. E. Diagnostic Systems
  • a diagnostic system in kit form of the present invention includes, in an amount sufficient for at least one assay, a monoclonal antibody of the present invention, as a separately packaged reagent.
  • a monoclonal antibody of the present invention is those produced by hybridoma LM609. Instructions for use of the packaged reagent are also typically included.
  • Instructions for use typically include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.
  • a diagnostic system of the present invention further includes a label or indicating means capable of signaling the formation of a complex produced by immunoreaction of ECr with a monoclonal antibody of this invention.
  • a label or indicating means capable of signaling the formation of a complex produced by immunoreaction of ECr with a monoclonal antibody of this invention.
  • the anti-ECr antibody molecules present in a monoclonal antibody composition of the present are linked to an indicating means.
  • complex refers to the product of a specific binding reaction such as an antibody-antigen or receptor-ligand reaction.
  • label and indicating means in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a complex.
  • "In vivo" labels or indicating means are those useful within the body of a subject and include 11:L In, 99 Tc, 67 Ga, 186 Re and 132 I. Any label or indicating means can be linked to or incorporated in the antibody molecule that is part of a monoclonal antibody composition of the present invention, or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents.
  • the labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer.
  • Suitable fluorescent labeling agents are fluorochromes such as fluorescein isocyanate (FIC) , fluorescein isothiocyante (FITC) , 5-dimethylamine-l- naphthalenesulfonyl chloride (DANSC) , tetramethylrhodamine isothiocyanate (TRITC) , lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC) and the like.
  • FIC fluorescein isocyanate
  • FITC fluorescein isothiocyante
  • DANSC 5-dimethylamine-l- naphthalenesulfonyl chloride
  • TRITC tetramethylrhodamine isothiocyanate
  • lissamine rhodamine 8200 sulphonyl chloride
  • the indicating group is an enzyme, such as horseradish peroxidase (HRP) , glucose oxidase, or the like.
  • HRP horseradish peroxidase
  • glucose oxidase or the like.
  • HRP horseradish peroxidase
  • additional reagents are required to visualize the fact that a paratopic molecule-antigen complex (immunoreactant) has formed.
  • Such additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine.
  • An additional reagent useful with glucose oxidase is 2,2'-azino-bis-(3-ethyl- benzthiazoline-sulfonic acid) (ABTS) .
  • Radioactive elements are also useful labeling agents and are used illustratively herein.
  • An exemplary radio labeling agent is a radioactive element that produces gamma ray emissions. Elements which themselves emit gamma rays, such as 124 I, 125 l, 128 I, 132 i and 5 ⁇ Cr represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly preferred is 125 I.
  • Another group of useful labeling means are those elements such as 1] -C, 18 F, 15 0 and 13 N which themselves emit positrons. The positrons so emitted produce gamma rays upon encounters with electrons present in the animal's body. Also useful is a beta emitter, such - ⁇ indium or 3 H.
  • labeling of, proteins is well known in the art.
  • antibody molecules produced by a hybridoma can be labeled by metabolic incorporation of radioisotope- containing amino acids provided as a component in the culture medium.
  • the techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas, et al., Scand. . Immunol ⁇ ,
  • the diagnostic systems can also include, preferably as a separate package, a specific binding agent.
  • a "specific binding agent” is a molecular entity capable of selectively binding a reagent species of the present invention or a complex containing such a species, but is not itself an antibody molecule composition of the present invention.
  • Exemplary specific binding agents are second antibody molecules, complement proteins or fragments thereof, S. aureus protein A, and the like.
  • the specific binding agent binds the reagent species when that species is present as part of a complex.
  • the specific binding agent is labeled.
  • the agent is typically used as an amplifying means or reagent.
  • the labeled specific binding agent is capable of specifically binding the amplifying means when the amplifying means is bound to a reagent species- containing complex.
  • the diagnostic kits of the present invention can be used in an "ELISA" format to detect the presence or quantity of ECr in a body fluid sample such as serum, plasma or urine.
  • ELISA refers to an enzyme-linked immunosorbent assay that employs an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen or antibody present in a sample.
  • a description of the ELISA technique is found in Chapter 22 of the 4th Edition of Basic and Clinical Immunology by D.P. Sites et al., published by Lange Medical Publications of Los Altos, CA in 1982 and in U.S. Patents No. 3,654,090; No. 3,850,752; and No. 4,016,043, which are all incorporated herein by reference.
  • a monoclonal antibody of the present invention can be affixed to a solid matrix to form a solid support that comprises a package in the subject diagnostic systems.
  • the reagent is typically affixed to the solid matrix by adsorption from an aqueous medium although other modes of affixation, well known to those skilled in the art, can be used.
  • Useful solid matrices are also well known in the art. Such materials are water insoluble and include the cross-linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals (Piscataway, NJ) ; agarose; beads of polystyrene beads about 1 micron to about 5 millimeters in diameter available from Abbott Laboratories of North Chicago, IL; polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.
  • a monoclonal antibody, labeled specific binding agent or amplifying reagent of any diagnostic system described herein can be provided in solution, as a liquid dispersion or as a substantially dry powder, e.g., in lyophilized form.
  • the indicating means is an enzyme
  • the enzyme's substrate can also be provided in a separate package of a system.
  • a solid support such as the before-described microtiter plate and one or more buffers can also be included as separately packaged elements in this diagnostic assay system.
  • the packages discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic systems.
  • Such packages include glass and plastic (e.g., polyethylene, polypropylene and polycarbonate) bottles, vials, plastic and plastic- foil laminated envelopes and the like.
  • the present invention contemplates any method that results in detecting ECr by producing an immunoreaction product using a monoclonal antibody of the present invention.
  • the anti-ECr antibody molecules used are those produced by hybridoma LM609.
  • hybridoma LM609 those produced by hybridoma LM609.
  • a method for detecting the presence of ECr contained within the body of a subject is contemplated.
  • a diagnostically effective amount of a monoclonal antibody of the present invention, wherein the anti-ECr antibody molecules present are linked to a in vivo indicating means, is intravenously administered into the subject.
  • the labeled antibodies are those that are secreted by hybridoma LM609.
  • a diagnostically effective amount of a monoclonal antibody is typically an amount of about 5 to about 1000 milligrams (mg) of the linked antibody in a pharmaceutically acceptable excipient per kg bodyweight of recipient, and more preferably about 10 to about 20 mg/kg.
  • the amount of monoclonal antibody utilized depends, inter alia, upon the condition of the subject and the type of indicating means linked to the antibody.
  • the subject is then maintained for a predetermined time period sufficient for the labeled antibody molecules to immunoreact with any ECr that is present and form an immunoreaction product, and preferably for an additional time period sufficient for a substantial amount of any non-reacted antibody molecules to clear the body.
  • the subject is then assayed for the presence and preferably the location of any labeled product that formed.
  • ECr in a Body Sample Various heterogeneous and homogeneous assay protocols can be employed, either competitive or non- competitive, for detecting the presence and preferably the amount of ECr in a body fluid sample such as blood or in a whole cell preparation such as a tissue section.
  • a preparation of tissue biopsy is prepared for immunofluorescence analysis by fixation and admixed with a monoclonal antibody of this invention containing anti-ECr antibody molecules labeled with glucose-oxidase.
  • the immunoreaction admixture thus formed is maintained under biological assay conditions for a time period sufficient for any ECr present in the sample to immunoreact with the labeled antibody molecules to form a labeled immunoreaction product.
  • the labeled immunoreaction products are then separated from the non-reacted labeled antibody molecules, typically by washing the fixed sample sufficient to rinse away all non-reacted labeled antibody molecules without removing significant amounts of immunoreacted antibody present in the sample.
  • the amount of labeled immunoreaction product formed is then assayed.
  • Biological assay conditions are those that maintain the biological activity of the antibody molecules of this invention and ECr sought to be assayed. Those conditions include a temperature range of about 4 degrees C to about 45 degrees C, preferably about 37 degrees C, a pH value range of about 5 to about 9, preferably about 7 and an ionic strength varying from that of distilled water to that of about one molar sodium chloride, preferably about that of physiological saline. Methods for optimizing such conditions are well known in the art. Examples
  • M21 human melanoma cells were kindly provided by Dr. D.L. Morton (University of California at Los Angeles, CA) . The isolation of the ECr was performed as previously described by Cheresh et al. , J. Biol. Chem.. 262:4 1434-1437 (1987). Briefly, M21 cells were grown as a suspension culture in growth medium [RPMI 1640 containing 2mM L-glutamine and 50 micrograms per milliliter (mg/ml) gentamicin sulfate; all from GIBCO Laboratories, Grand Island, NY] containing 10 percent fetal calf serum (FCS) at 37 degrees C in 7.5% C ⁇ 2/95% air.
  • FCS fetal calf serum
  • extraction buffer phosphate buffered saline (PBS) containing 1 mM CaCl 2 , 1 mM MgCl , 100 mM octyl beta-D-glucopyranoside (octylglucoside; Behring Diagnostics, La Jolla, CA) , 3 mM phenylmethyl sulfonyl flouride (PMSF) ] .
  • PBS phosphate buffered saline
  • PMSF phenylmethyl sulfonyl flouride
  • GRGDSPK Gly-Arg-Gly-Asp-Ser-Pro-Lys
  • Proteins contained in the eluted fractions so analyzed were visualized on the SDS-PAGE gels by autoradiography.
  • the apparent molecular weight (Mr) of the visualized proteins was determined by comparison to protein molecular weight markers also analyzed on the gel that include myosin, 200; beta-galactosidase, 116; phosphorylase B, 94; bovine serum albumin, 67; ovalbumin, 43; and carbonic anhydrase, 30; all molecular weights in units of one thousand daltons.
  • Hybridoma Formation Hybridomas that secrete antibody molecules that immunoreact with ECr were prepared by immunization with ECr-bound Sepharose beads prepared in Example 2a. One hundred microliters (ul) of a suspension containing 50 ul PBS and 50 ul of ECr-bound Sepharose beads were injected intraperitoneally (ip) once every week for a total of 6 weeks into Balb/c mice.
  • mice Three days after the last injection, the splenocytes of these mice were removed, a suspension of the splenocytes was made, and the splenocytes were fused with a non-secreting murine myeloma cell line Sp2/0 subclone M5 in the presence of a cell fusion promoter (polyethylene glycol 2000, Boehringer Mannheim Biochemicals, Indianapolis, IN) to form hybridomas using the standard hybridoma technology described by Galfre et al., Meth. Enzymol.. 73:3-46 (1981) .
  • a cell fusion promoter polyethylene glycol 2000, Boehringer Mannheim Biochemicals, Indianapolis, IN
  • the resulting hybridomas were selected by growth in a culture medium that does not support the growth of unfused myeloma cells and contains hypoxanthine, aminopterin and thymidine (HAT) , and were thereafter subcloned using limiting dilution and culturing in separate containers.
  • the resulting culture supernatant in each container was then evaluated for the presence of antibody molecules that immunoreact with (bind to) ECr contained on intact M21 •cells using the ELISA assay described in Example 2c. c. Screening Hybridomas by M21 Cell
  • ELISA M21 cells cultured as described in Example 1, were washed twice in normal saline and plated in a flat-bottom polyvinyl microtiter plate (Dynatech, Chantilly, VA) at 5 X 10 4 cells per well in 50 ul in growth medium containing 10% FCS. Thereafter the plates were maintained at 37 degrees C for about 12-18 hours to dry the plates.
  • Dried plates were rehydrated by two washes each comprising first the addition of wash buffer [10 mM PBS, pH 7.4, 0.1% Tween 20 (polyoxyethylenesorbitan monolaurate) 0.02% thimerosal (sodium ethylmercurithiosalicylate) ] , then the maintenance of the plates at room temperature for two minutes, and finally the removal of the liquid by inverting the plates.
  • wash buffer 10 mM PBS, pH 7.4, 0.1% Tween 20 (polyoxyethylenesorbitan monolaurate) 0.02% thimerosal (sodium ethylmercurithiosalicylate)
  • the plates were maintained for one hour at 4 degrees C on a gyroshaker, emptied of their liquid contents by inversion and shaking, and then washed twice as described above to isolate solid- phase bound immunoreaction products.
  • Hybridomas LM142 and LM609 were then further screened for the ability to secrete antibody molecules that could inhibit adhesion of M21 melanoma cells to vitronectin using the adhesion assay described in Example 5.
  • Hybridomas of the present invention are those which secrete anti-ECr antibody molecules capable of reducing by greater than 50% the amount of M21 cells that attach when compared to the amount that attach in the presence of a heterologous monoclonal antibody (negative control) .
  • a monoclonal antibody of the present invention is prepared from a hybridoma culture supernatant by separating the supernatant from the. hybridoma cells to form a cell-free antibody molecule- containing solution.
  • a monoclonal antibody can be produced from ascites by introducing, as by injection, a hybridoma prepared in Example 2 into the peritoneal cavity of a mammal such as a mouse and later harvesting the resulting peritoneal exudate (ascites tumor fluid) from the mouse by well known techniques.
  • Anti-ECr antibody molecules present in recovered antisera, ascites fluid or hybridoma culture supernates can then be further isolated by affinity chromatography using protein-A Sepharose (Bio-Rad Laboratories, Richmond, CA) according to the methods recommended by the manufacturer with the exception that the elution buffer should be adjusted to pH 5.0-
  • the protein concentration of the resulting protein-A Sepharose isolated antibody containing- soluti ⁇ ns was determmined typically using the Bio-Rad Protein Assay Kit (Bio-Rad, Richmond, CA) according to the manufacturer's instructions.
  • M21 melanoma cells described in Example 1 were maintained at a concentration of 3.5 X 10 7 cells/ml for 15 minutes at 37°C in methionine-free growth medium (GIBCO) containing 10% FCS. Subsequently, 35 S-methionine was admixed with the cells to a concentration of 0.5-lmCi/ml. After maintaining the cells for 10 minutes 5 X 10 6 cells were then removed and designated as zero time point cells. The remaining cells were centrifuged at 400 x g to separate them from free 35 S-methionine and the resulting pellet was washed four times in growth medium containing 4 mM unlabeled L-methionine.
  • GEBCO methionine-free growth medium
  • Lysates were then prepared by resuspending the labeled M21 cell pellet in RIPA lysis buffer (0.1 M Tris-HCr [Tris (hydroxymethyl) amino methane hydrochloride] , pH 7.2, 0.15 M NaCl, 1% (w/v) deoxycholate, 1% (w/v) Nonident P-40 (an octylphenol ethylene oxide condensate containing an average of 9 moles ethylene oxide per phenol; Sigma), 0.1% (w/v) SDS, 10% (w/v) aprotinin (Sigma, product No. A6279) , 2 mM PMSF) at a concentration of 10 6 cells/ml.
  • RIPA lysis buffer 0.1 M Tris-HCr [Tris (hydroxymethyl) amino methane hydrochloride] , pH 7.2, 0.15 M NaCl, 1% (w/v) deoxycholate, 1% (w/v) Nonident P-40 (an octylphenol ethylene oxide conden
  • the resulting lysates were maintained for 15 min at 0 °C to ensure maximum cell lysis and then were subjected to ultracentrifugation at 35,000 rpm in a Beckman Ti50 rotor (Beckman Instruments, Palo Alto, CA) for 45 minutes to clear cell debris and form a 35 S-labeled cell lysate.
  • Ten mg of antibody protein isolated using protein A-Sepharose as described in Example 3 were covalently coupled to 1 ml of cyanogen bromide- activated Sepharose (Pharmacia) according to the manufacturer's instructions to form immunoadsorbant beads.
  • a suspension containing 10 ul of packed immunoadsorbant beads in 100 ul RIPA lysis buffer was admixed with 1 ml clear labeled lysate to form an immunoreaction admixture.
  • the admixture was then maintained overnight (16-18 hours) at 4°C to allow formation of M21 ECr-immunoadsorbant bead complexes containing an immunoreaction product.
  • the beads were then centrifuged at 12,000 x g for about ten seconds at 20 degrees C, and the resulting pellet was recovered and washed five times in 1 ml volumes of phosphate-buffered saline, pH 7.2 containing 0.1% ovalbumin and 0.5% Tween 20.
  • the immunoreaction product was solubilized by boiling for 3 minutes in 100 ul of sample buffer (30 mM Tris-HCl, pH 6.8, 10% glycerol and bromphenol blue) and analyzed by SDS-PAGE under reducing conditions on 7.5% gels according to the methods of Laemmli, Nature. 227:680-685 (1970) .
  • the labeled protein bands were visualized on SDS-PAGE gels by autoflourography.
  • the apparent molecular weights (Mr) of the visualized proteins were determined as described in Example 1.
  • the M21 cells were grown in suspension culture in RPMI 1640 growth medium containing 10% fetal calf serum (FCS) at 37°C with 7.5% C0 2 /92.5% air. These cells were metabolically labeled in leucine-free growth media containing 50 microCuries
  • the wells of polystyrene microtiter plates (96-well; Flow Laboratories, McLean, VA) were coated with matrix proteins (adhesion substrates) by admixing solutions of PBS (pH 7.2) containing 5-20 ug/ml of an adhesion substrate to a well.
  • the wells were maintained overnight at 25 degrees C to allow adsorption of the proteins onto the wells.
  • RISC von Willebrand factor and size fractionated von Willebrand factor, wherein pool I contains large multimers of greater than 5 X 10 3 kDa and pool III contains multimers from 2-5 X 10 3 kDa all being provided by Drs. Z. Ruggeri and T. Zimmerman (RISC) ; collagen type I and IV (Collaborative
  • the plates were then inverted to remove the peptide coating solution from the wells. Residual uncoated sites were blocked by admixing a solution of PBS containing 1% BSA into each well and maintaining the wells for 1 hour at room temperature to form peptide (adhesion substrate) coated wells. Fifty ul of growth medium containing 5 X 10 3 antibody treated M21 cells were admixed in an adhesion substrate-coated well to form an adhesion-reaction admixture. The admixtures were maintained at 37 degrees C in a humidified incubator for the times indicated in Figure 2, at which point the plates were inverted to remove growth medium and non-adhered cells.
  • ECr from metabolically labeled human umbilical vein endothelial (HUVE) cells was prepared by first isolating HUVE cells from fresh human umbilical veins and then propagating the isolated cells as described by Jaffe et al., J. Clin. Invest..
  • HUVE cells were then labeled by the addition of 2 microCuries of 35 S-methionine (1295 Ci/millimole, New England Nuclear) to a T-150 tissue culture flask (Corning Glass, Corning, NY) containing the cells at semi-confluency in 20 ml of growth medium (RPMI 1640 containing 10% FCS) . The culture was then maintained for 72 hours at 37°C to allow formation of 35 S-labeled HUVE cells.
  • S-methionine 1295 Ci/millimole, New England Nuclear
  • the labeled HUVE cells were then harvested by adding sufficient versene [10 mM ethylene- diaminetetraacetic acid (EDTA) in PBS] to cover the monolayer of labeled cells, maintaining the monolayer at 37 degrees for about 10 minutes or until the monolayer cells become detached from the culture flask and then collecting the detached cells.
  • the detached cells were then centrifuged in a clinical centrifuge at 1500 rpm for about 5 minutes to form a labeled HUVE cell pellet.
  • the resulting pellet was admixed with an equal volume of extraction buffer (PBS containing 1 mM CaCl 2 , 1 mM MgCl 2 , 100 mM octylglucoside, and 3 mM PMSF) .
  • the admixture was maintained for 15 minutes at 4°C, centrifuged at 25,000 x g for 30 minutes and the resulting supernate was then recovered to form a labeled HUVE cell extract.
  • BAE cells bovine aortic endothelial (BAE) cells were used utilized as a bovine source of ECr for immunoprecipitation analysis.
  • BAE cells were isolated from the aorta of cows by the method of Booyse et al. , Thromb. Diathes. Haemorrh. f 34:825 (1975), whose teachings are incorporated herein by reference. Isolated BAE cells were cultured in modified Eagle's medium supplemented with 10 percent FCS as described in Levin et al., Thromb. Res.. 15:869 (1979).
  • Example 6 Cultured BAE cells were labeled with 35 S- methionine and harvested as in Example 6 to form a labeled BAE cell pellet. Lysate preparation and immunoprecipitation analysis were then performed on the labeled BAE cell pellet as described in Example 4. Immunoadsorbants prepared from Mab LM609 immunoreacted with ECr present in BAE lysates as indicated by the presence in the immunoreaction products of proteins having molecular weights of about 135 kDa, i.e., molecular weights corresponding to the alpha and beta subunits, respectively, of ECr detected in HUVE cells. 8.
  • Human endothelial Cell Adhesion Assay Human umbilical vein endothelial (HUVE) cells were grown in monolayer cultures as described in Example 6. The HUVE cell monolayers were metabolically labeled by maintaining cells for 72 hours at 37°C in growth medium containing 50 uCi/ l 3 H-leucine. The labeled cells were detached from the monolayer culture flask using a Trypsin/EDTA solution as is well known and then washed in growth medium containing 1% FCS by low speed centrifugation in the same medium to form 3 H-leucine labeled HUVE cells.
  • HUVE Human umbilical vein endothelial
  • the 3 H-leucine labeled HUVE cells were analyses in the adhesion assay in the same manner as the 3 H-leucine labeled M21 cells were analyzed as described in Example 5. Those cells which adhered to adhesion substrate coated wells were then harvested and the radioactivity contained therein determined as described in Example 5.
  • Mab LM609 but not heterologous Mab W6/32 immunoreacted with HUVE cells and significantly inhibited their adhesion (attachment) to fibrinogen, vitronectin, von
  • ECr was isolated from M21 melanoma cells as described in Example 1.
  • the resulting isolated ECr- containing solutions were concentrated approximately 22 fold using a Centricon 30 microconcentrator (Amicon Corp, Danvers, MA; product No. 4209) according to the manufacturer's instructions using 0.05% SDS in HPLC grade water.
  • the resulting concentrated ECr- containing solution was subjected to amino acid sequence analysis using an Applied Biosystems model 470 sequenator equipped with on-line PTH analysis using sequencing program 03RPTH, all according to the methods of and with materials provided by the manufacturer. (Applied Biosystems, Inc., Foster City, CA) .
  • each residue analyzed at a given position yielded two different amino acids.
  • the alpha subunit sequence of ECr was obtained by "subtracting" from the amino acid residues found at each position in the residues that corresponded to the known beta subunit sequences of VNr and GPIIb-IIIa.
  • the partial amino acid sequence of ECr is shown in Figure 6.
  • a comparison of the partial amino acid sequence of the alpha and beta subunits of ECr to the respective subunits of vitronectin receptor or GpIIb-IIIa is also presented in Figure 6. This initial and partial amino acid sequence analysis of the amino terminus indicates that ECr is similar but not identical to VNr or GpIIb-IIIa.
  • the monoclonal antibodies used in this analysis include LM142 and LM609, prepared in Example 2; LM534 provided by Dr. Cheresh (SCRF) that is directed to the FNr beta subunit; AP3, provided by Dr. Peter Newman (The Blood Center of Southeastern Wisconsin, (Milwaukee, WI) , that is directed to the platelet glycoprotein Ilia [GpIIIa; Newman et al., Blood. 65:227-232 (1985)]; and W6/32, provided by
  • A375P is a sub-clone of A375 (ATCC CRL 1619) , and was obtained from Dr. J. Fidler (University of Texas Health Sciences Center, Houston, TX) ; A375MM (Dr. J. Fidler) ; Melur (Dr. U. Kodovsky, Dusseldorf, West Germany) ; WM266 and WM239a (Dr. M. Hierlyn, Wistar Inst., Philadelphia, PA); neuroblastoma:. SK-N- AS (Dr. Helson, Memorial Sloan-Kettering Cancer Center, NY) ; SMS-KCNR, SMS-KCN, NMB-7 and IMR-6 (Dr. P.
  • pancreatic carcinoma Colo 357 FG and Colo 357 SG (Dr. Kajiji, Scripps Clinic, La Jolla, CA) ; pancreatic carcinoma: Colo 357 FG and Colo 357 SG (Dr. Kajiji, Scripps Clinic, La Jolla, CA) ; astrocytoma/glioblastoma: U373 MG (ATCC HTB 17) ; U138 MG (ATCC HTB16) ; U87 MG (ATCC HTB 14) ; T-cell lymphoma: HPB-ALL; Molt-4 (ATCC CRL 1582) ; HSB-2 (Dr. R. Fox, Scripps Clinic and Research Foundation, La Jolla, CA) ; B-cell lymphoblastoid: L14 and LG2 (Dr. Gati, UCLA); 3160,; 3107, 1857 and 3098 (NIGMS Human Genetic Mutant Cell Repository, NIH, Bethesda, MD) ; monocytic: U 9
  • Figure 7 shows that ECr or antigenically related proteins which immunoreact with LM609 are present on the surface of most of the melanoma cell lines examined and on some other tumor cell types., albeit in lesser amounts. It is believed that all cell types exhibiting significant immunoreaction with Mab LM609 contain ECr on their surface and thus are representative targets for the therapeutic and diagnostic methods of the present invention.
  • Booster injection of ECr are administered at multiple intradermal sites (typically 100 ug distributed over 4 sites) in incomplete Freund's adjuvant on a weekly schedule for an additional three months. Antisera is then harvested using well known techniques. b. Immunoprecipitation Analysis to Detect a Complex-Dependent Monoclonal Antibody
  • M21 melanoma cells were obtained and cultured as described in Example 1. M21 cells were then maintained at a concentration of 3.5 X 10 7 cells/ml for 15 minutes at 37°C in methionine-free growth medium (GIBCO) containing 10% FCS. Subsequently, 35 S-methionine was admixed with the cells to a concentration of 0.5-1 mCi/ml and the culture was then maintained at 37°C for 2 minutes to form labeled M21 cells. One culture of labeled M21 cells was then retained, the labeling medium removed and the remaining cells were designated as zero ti epoint labeled M21 cells.
  • GEBCO methionine-free growth medium
  • Lysates are then prepared and immunoprecipitation analysis is conducted as described in Example 4 using both the anti-ECr control antisera from Example 12a and separately a monoclonal antibody of interest. If there is a delay of about 5 minutes in the detection time of the ECr alpha subunit precursor of about 160 kilodaltons (kDa) when using a Mab of interest in comparison to the detection time when using the control antisera, that Mab is designated a complex-dependent Mab, i.e., a Mab that immunoreacts with a complex-dependent determinant. For example, the results of an analysis for a complex-dependent Mab is shown in Figure 8. Lysates of M21 cells pulse-chase labeled as described above were analyzed by immunoprecipitation using Mab LM142 (panel A) , Mab LM609 (panel B) or Mab AP3 (panel C) .
  • Immunoprecipitation analysis using Mab LM142 shows the detection in M21 cell pulse-chase lysates of the ECr alpha subunit precursor of about 160 kDa.
  • the alpha subunit precursor was detectable at the zero time point and was continuously detectable throughout the chase period to 120 minutes.
  • Mab LM609 detects the alpha subunit precursor in those same M21 cell lysates after a chase period of about 5 minutes and throughout the remaining chase period but not at the initial zero time point.
  • the 5 minute delay in detection indicates that Mab LM609 is not capable of immunoreaction with the alpha subunit precursor until that subunit undergoes processing to form a heterodimer complex during the time between the zero time point and the 5 minute chase time point.
  • Mab LM142 is characterized as being capable of immunoreaction with a complex-independent determinant present on the alpha subunit precursor whereas Mab LM609 immunoreacts with a complex-dependent determinant.
  • Immunoprecipitation analysis using Mab AP3 shows the detection in M21 cell pulse-chase lysates of both the alpha subunit precursor and the 105 kDa beta subunit protein. Both proteins appear after a chase of about 10 minutes and persist in M21 cells for at least 120 minutes. Therefore the beta subunit is present and detectable in ECr-containing cells after 10 minutes of chase when using Mabs that immunoreact with the beta subunit of ECr, such as Mab AP3.
  • the beta subunit is not detectable in the same M21 cell lysates at times before a chase period of 120 minutes when using a complex-dependent Mab, e.g., LM609, or when using an alpha subunit specific Mab, e.g., LM142.
  • a complex-dependent Mab is therefore further characterized as being incapable of detecting the beta subunit of ECr at times earlier than about 120' of chase as shown in panel B of Figure 8.
  • heterodimer complex formation in the absence of a detectable 105 kDa beta subunit for example as shown in panel B at chase times of 5 to 60 minutes, can be explained by differences in incorporation of label into the intracellular pool of beta subunit proteins when compared to incorporation into a pool of alpha subunit proteins available for heterodimer complex formation.
  • the beta subunit incorporates label within 10 minutes of chase (panel B, 10') and is thereby detectable using beta subunit specific Mab AP3.
  • labeled beta subunit does not associate with alpha subunit to form a heterodimer complex until after about 120 minutes at which time the complex immunoreacts with either alpha subunit specific Mab LM142 (panel A) or complex-dependent Mab LM609 (panel B) .
  • any immunoreaction product formed from lysates prepared prior to 120 minutes of chase appear to contain only the alpha subunit precursor because the beta subunit is present in the product as an unlabeled species.
  • the determination that a Mab immunoreacts with a complex-dependent determinant can be carried out as shown herein above, or it may be similarly accomplished using other reagent materials.
  • any cell line that contains ECr may be utilized as a source of the pulse-chase labeled ECr- containing lysate.
  • Exemplary of said ECr-containing cells are BAE cells, HUVE cells, M21 melanoma cells and A375 melanoma cells (ATCC CRL 1619) .
  • Control antisera such as that produced in Example 12a, may be used as a source of complex-independent antibody molecules.
  • the control antisera when used in immunoprecipitation analyses of the above M21 cell lysates, exhibits the temporal pattern of immunoreaction with the alpha subunit precursor that begins at the zero time point characteristic of complex-independent antibody molecules.

Abstract

La présente invention décrit un anticorps monoclonal qui entre en immunoréaction avec l'ECr, qui est le récepteur d'adhésion dirigé sur la séquence RGD, récepteur qu'on trouve sur la surface de cellules de l'endothélium et du mélanome. Des procédés grâce auxquels cet anticorps monoclonal peut être utilisé pour inhiber le pouvoir de cellules contenant ce récepteur d'adhésion d'adhérer à une matrice subendothéliale composée de vitronectine de fibrogène ou du facteur von Willebrand sont également décrits. Des systèmes et des procédés diagnostiques servant à détecter par analyses la présence d'ECr dans un échantillon corporel au moyen de l'anticorps de la présente invention sont également décrits.
PCT/US1988/004118 1987-11-19 1988-11-17 Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales WO1989005155A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FI893475A FI893475A (fi) 1987-11-19 1989-07-18 Monoklonal antikropp mot en rgd-riktad adhesionreceptor av endotelceller.
NO89892941A NO892941L (no) 1987-11-19 1989-07-18 Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.
DK355589A DK355589A (da) 1987-11-19 1989-07-18 Monoklonalt antistof mod endotelcellers rgd-rettede adhaesionsreceptor, hybridom til produktion af antistofferne, samt analyse for tilstedevaerelsen af ovennaevnte receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12304587A 1987-11-19 1987-11-19
US123,045 1987-11-19

Publications (1)

Publication Number Publication Date
WO1989005155A1 true WO1989005155A1 (fr) 1989-06-15

Family

ID=22406412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/004118 WO1989005155A1 (fr) 1987-11-19 1988-11-17 Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales

Country Status (5)

Country Link
EP (1) EP0341303A4 (fr)
JP (1) JPH02502156A (fr)
AU (1) AU2807189A (fr)
FI (1) FI893475A (fr)
WO (1) WO1989005155A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020229A1 (fr) * 1992-04-03 1993-10-14 Genentech, Inc. ANTICORPS DE L'INTEGRINE ALPHA v BETA 3
EP0669988A1 (fr) † 1992-10-29 1995-09-06 The Australian National University Anticorps inhibant l'angiogenese
WO1995025543A1 (fr) * 1994-03-18 1995-09-28 The Scripps Research Institute Compositions inhibitrices de l'angiogenese et procedes correspondants
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1998040488A1 (fr) * 1997-03-12 1998-09-17 Smithkline Beecham Corporation Anticorps monoclonaux humanises anti-alphabeta 3
WO1998046265A1 (fr) * 1997-04-11 1998-10-22 G.D. Searle & Co. PROCEDES D'UTILISATION D'ANTICORPS QUI SONT DES ANTAGONISTES DE L'INTEGRINE αvβ¿3?
WO1998046264A1 (fr) * 1997-04-11 1998-10-22 G.D. Searle & Co. Anticorps de l'integrine a action antagoniste anti-avb3
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6500924B1 (en) 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
WO2011020529A3 (fr) * 2009-08-19 2011-06-16 Merck Patent Gmbh Anticorps pour la détection de complexes d'intégrine dans une matière ffpe

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
See also references of EP0341303A4 *
The Journal of Biological Chemistry, Volume 262, No. 21, issued 25 July 1987 (Baltimore, Maryland, USA), I.F. CHARO, "Platelet Glycoprotein II-b-IIIa-like Proteins Mediate Endothelial Cell Attachment to Adhesive Proteins and the Extracellular Matrix", see page 9936, column 2, lines 15-25, page 9937, column 1, line 5-column 2, line 7 and page 9938, column 1, lines 10-24. *
The Journal of Biological Chemistry, Volume 262, No. 36, issued 25 December 1987 (Balitmore, Maryland, USA), D.A. CHERESH, "Biosynthetic and Functional Properties of an Arg-Gly-Asp-Directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor", see page 17703, column 2, lines 1-5 and 24-43 and page 17710, column 1, lines 21-24 and column 2, lines 1-15. *
The Journal of Biological Chemistry, Volume 262, No. 4, issued 05 February 1987 (Balitmore, Maryland, USA), D.A. CHERESH, "Arg-Gly-Asp Recognition by a Cell Adhesion Receptor Requires its 130 KDa Subunit", see page 1434, column 2, lines 7-15, page 1435, column 1, lines 13-18, page 1437, column 1, lines 10-15 and line 41-column 2, line 7. *
The Journal of Immunology, Volume 138, No. 10, issued 15 May 1987 (Baltimore, Maryland, USA), J.R. ORTALDO, "Analysis of Effector Cells in Human Antibody-Dependent Cellular Cytotoxicity with Murine Monoclonal Antibodies", see page 3566, column 2, lines 25-34, page 3567, column 2, lines 38-45 and page 3571, column 2, lines 31-43. *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6395873B1 (en) 1990-04-06 2002-05-28 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5652109A (en) * 1992-04-03 1997-07-29 Genentech, Inc. Antibodies to αvβ3 integrin
US6359126B1 (en) 1992-04-03 2002-03-19 Genentech, Inc. Antibodies to αvβ3 integrin
US5652110A (en) * 1992-04-03 1997-07-29 Genentech, Inc. Antibodies to αvβ3 integrin
US5578704A (en) * 1992-04-03 1996-11-26 Genentech, Inc. Antibody to osteoclast alphavbeta3 ntegrin
WO1993020229A1 (fr) * 1992-04-03 1993-10-14 Genentech, Inc. ANTICORPS DE L'INTEGRINE ALPHA v BETA 3
US6369204B1 (en) 1992-04-03 2002-04-09 Genentech, Inc. Antibodies to αvβ3 integrin
EP0669988B2 (fr) † 1992-10-29 2009-07-08 The Australian National University Anticorps inhibant l'angiogenese
EP0669988A1 (fr) † 1992-10-29 1995-09-06 The Australian National University Anticorps inhibant l'angiogenese
US5766591A (en) * 1994-03-18 1998-06-16 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP1468695A1 (fr) * 1994-03-18 2004-10-20 The Scripps Research Institute Compositions inhibitrices de l'angiogenèse et procédés correspondants
US7595051B2 (en) 1994-03-18 2009-09-29 The Scripps Research Institute Methods of treating neovascular glaucoma, macular degeneration and capillary proliferation with alphavbeta3-specific antibodies
WO1995025543A1 (fr) * 1994-03-18 1995-09-28 The Scripps Research Institute Compositions inhibitrices de l'angiogenese et procedes correspondants
US7482007B2 (en) * 1994-03-18 2009-01-27 The Scripps, Research Institute Methods of inhibiting angiogenesis to treat cancer with alphavbeta3-specific antibodies
US7354586B2 (en) 1994-03-18 2008-04-08 The Scripps Research Institute Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies
US6887473B1 (en) 1994-03-18 2005-05-03 The Scripps Research Institute Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP1410807A1 (fr) * 1994-03-18 2004-04-21 The Scripps Research Institute Compositions inhibitrices de l'angiogenese et procedes correspondants
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US6500924B1 (en) 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1998040488A1 (fr) * 1997-03-12 1998-09-17 Smithkline Beecham Corporation Anticorps monoclonaux humanises anti-alphabeta 3
EP1491632A3 (fr) * 1997-03-12 2006-01-04 Smithkline Beecham Corporation Anticorps monoclonaux humanisés anti-alphavbeta 3
EP1491632A2 (fr) * 1997-03-12 2004-12-29 Smithkline Beecham Corporation Anticorps monoclonaux humanisés anti-alphavbeta 3
US7230083B2 (en) 1997-03-12 2007-06-12 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US7504102B2 (en) 1997-03-12 2009-03-17 Smithkline Beecham Corporation Anti-αvβ3 humanized monoclonal antibodies
US6171588B1 (en) 1997-04-11 2001-01-09 G. D. Searle & Company Anti-αvβ3 integrin antibody antagonists
WO1998046265A1 (fr) * 1997-04-11 1998-10-22 G.D. Searle & Co. PROCEDES D'UTILISATION D'ANTICORPS QUI SONT DES ANTAGONISTES DE L'INTEGRINE αvβ¿3?
WO1998046264A1 (fr) * 1997-04-11 1998-10-22 G.D. Searle & Co. Anticorps de l'integrine a action antagoniste anti-avb3
US6193968B1 (en) 1997-04-11 2001-02-27 The Burnham Institute Methods for using anti-αvβ3 integrin antibody
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
WO2011020529A3 (fr) * 2009-08-19 2011-06-16 Merck Patent Gmbh Anticorps pour la détection de complexes d'intégrine dans une matière ffpe
US8420348B2 (en) 2009-08-19 2013-04-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Antibodies for the detection of integrin complexes in FFPE material
US8993261B2 (en) 2009-08-19 2015-03-31 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
EA032728B1 (ru) * 2009-08-19 2019-07-31 Мерк Патент Гмбх Антитела для выявления комплексов интегрина в ffpe материале

Also Published As

Publication number Publication date
EP0341303A4 (fr) 1990-06-27
AU2807189A (en) 1989-07-05
EP0341303A1 (fr) 1989-11-15
FI893475A0 (fi) 1989-07-18
JPH02502156A (ja) 1990-07-19
FI893475A (fi) 1989-07-18

Similar Documents

Publication Publication Date Title
US5284751A (en) Antibodies that bind to a ligand-induced binding site on GPIIIa
US5306620A (en) Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US5372933A (en) Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5262520A (en) Peptides and antibodies that inhibit integrin-ligand binding
US5599790A (en) Fibrinogen γ chain polypeptide and compositions thereof
WO1989005155A1 (fr) Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales
CA2069902A1 (fr) Peptides et anticorps qui inhibent la liaison des integrines-ligands
US5473051A (en) Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
WO1990014103A1 (fr) Conjugue polypeptide-anticorps empechant l'adhesion des cellules
CA1307479C (fr) Methodes diagnostiques et systemes pour quantifier un apo ai
CA2190262A1 (fr) Anticorps monoclonal specifique d'un antigene endoglyx-1 de cellules endotheliales vasculaires, l'antigene lui-meme et ses utilisations
EP0524737A2 (fr) Polypeptides de la protéine S et anticorps anti-peptide qui inhibent la liaison de la protéine S à la protéine de liaison de C4b, systèmes de diagnostic et procédés thérapeutiques
US6323324B1 (en) Test kits for detecting the presence of C-terminal hGPIIb fragments
AU675073B2 (en) Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
NO892941L (no) Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.
AU649800C (en) Monoclonal antibodies against receptor-induced binding sites
AU622117B2 (en) Peptides and antibodies that inhibit platelet adhesion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989900512

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 893475

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1989900512

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989900512

Country of ref document: EP